Atara Biotherapeutics Inc. (NASDAQ:ATRA) COO Gad Soffer sold 16,718 shares of the firm’s stock in a transaction on Wednesday, November 16th. The stock was sold at an average price of $20.00, for a total value of $334,360.00. Following the sale, the chief operating officer now directly owns 225,667 shares of the company’s stock, valued at $4,513,340. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Gad Soffer also recently made the following trade(s):

  • On Monday, November 14th, Gad Soffer sold 9,582 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $20.55, for a total value of $196,910.10.

Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) opened at 18.05 on Monday. Atara Biotherapeutics Inc. has a one year low of $12.45 and a one year high of $40.80. The company’s 50 day moving average price is $16.82 and its 200 day moving average price is $19.56. The stock’s market capitalization is $520.92 million.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Friday, November 4th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by $0.10. On average, analysts expect that Atara Biotherapeutics Inc. will post ($3.05) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Hedge funds have recently added to or reduced their stakes in the company. Bridger Management LLC acquired a new stake in Atara Biotherapeutics during the first quarter worth approximately $14,072,000. FMR LLC raised its stake in Atara Biotherapeutics by 29.9% in the second quarter. FMR LLC now owns 3,125,407 shares of the company’s stock worth $70,353,000 after buying an additional 720,313 shares in the last quarter. Slate Path Capital LP acquired a new stake in Atara Biotherapeutics during the second quarter worth approximately $9,454,000. BlackRock Fund Advisors raised its stake in Atara Biotherapeutics by 18.6% in the second quarter. BlackRock Fund Advisors now owns 913,922 shares of the company’s stock worth $20,572,000 after buying an additional 143,242 shares in the last quarter. Finally, Redmile Group LLC raised its stake in Atara Biotherapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 2,408,970 shares of the company’s stock worth $54,226,000 after buying an additional 133,205 shares in the last quarter. 74.45% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently issued reports on the company. Canaccord Genuity set a $47.00 target price on Atara Biotherapeutics and gave the company a “buy” rating in a report on Sunday, November 6th. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 2nd. Jefferies Group restated a “buy” rating and issued a $25.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, August 9th. Goldman Sachs Group Inc. lowered Atara Biotherapeutics from a “neutral” rating to a “sell” rating and reduced their target price for the company from $23.00 to $16.00 in a report on Thursday, September 15th. Finally, Citigroup Inc. increased their target price on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a report on Friday, August 19th. Three equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $25.86.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.